Medicine information provision system, medicine information provision method, and medicine information provision program

Abstract

A server device comprises: a reception unit that receives, from an inspection system, color development data indicating that the color development state of a test piece to which a sample is applied includes abnormal development of color; a creation unit that creates, for the received color development data, drug information relating to a drug that affects the abnormal color development of the test piece; and a transmission unit that transmits the created drug information to the inspection system.

Description

Drug Information Providing System, Drug Information Providing Method, and Drug Information Providing Program

[0001] The present disclosure relates to a drug information providing system, a drug information providing method, and a drug information providing program.

[0002] For example, Japanese Patent No. 5570240 describes a system capable of determining whether a drug administered to a subject may affect the test results of a sample such as urine or blood when testing the sample.

[0003] By the way, in qualitative tests of samples such as urine, test strips may not develop color normally due to the influence of drugs. For some drugs, the relationship with abnormal color development is known, so it is possible to identify the drug causing the abnormal color development as in the technology described in the above Patent Document 1.

[0004] On the other hand, in order to associate the relationship between abnormal color development and drugs, the accumulation of the knowledge and expertise of inspection personnel such as doctors and medical technicians is required. However, depending on the scale and region of medical facilities such as hospitals and testing centers, the knowledge and expertise of inspection personnel may not be sufficiently accumulated. In such medical facilities, it is difficult for inspection personnel to identify the cause of abnormal color development.

[0005] In addition, when a new drug is in circulation, the relationship between the new drug and the abnormal color development of test strips may be unclear. Even in such cases, it is difficult for inspection personnel to identify the cause of abnormal color development.

[0006] An object of the present disclosure is to provide a drug information providing system, a drug information providing method, and a drug information providing program that can easily identify the drug causing abnormal color development even in the case of medical facilities where the knowledge and expertise of inspection personnel are not sufficiently accumulated or in the case of new drugs.

[0007] To achieve the above objective, a drug information provision system according to one aspect of the present disclosure is a drug information provision system including an inspection system for inspecting a sample and a server device that is communicably connected to the inspection system, wherein the server device includes a receiving unit that receives color data from the inspection system indicating that the color development state of a test piece to which the sample has been applied is abnormally colored, a creation unit that creates drug information relating to a drug that affects the abnormal color development of the test piece based on the color data received by the receiving unit, and a transmission unit that transmits the drug information created by the creation unit to the inspection system.

[0008] According to this disclosure, even in medical facilities where the knowledge and expertise of the testing personnel are not sufficiently accumulated, or in the case of novel drugs, it is possible to easily identify the drug causing the abnormal coloration.

[0009] This is a schematic perspective view showing an example of an inspection system according to the first embodiment. This is a block diagram showing an example of the configuration of an inspection system according to the first embodiment. This is a diagram showing an example of image data and comments on a test strip according to the embodiment. This is a diagram showing a printing example including a flag indicating abnormal color development. This is a diagram showing an example of the configuration of a drug information provision system according to the first embodiment. This is a block diagram showing an example of the functional configuration of a server device according to the first embodiment. This is a diagram showing an example of image data and drug information displayed on the inspection device. This is a flowchart showing an example of the drug information learning process flow by a drug information provision program according to the first embodiment. This is a flowchart showing an example of the drug information provision process flow by a drug information provision program according to the first embodiment. This is a block diagram showing an example of the functional configuration of a server device according to the second embodiment.

[0010] Hereinafter, an example of an embodiment for carrying out the technology of this disclosure will be described in detail with reference to the drawings. Components and processes that perform the same operation, action, or function are given the same reference numerals throughout the drawings, and redundant explanations may be omitted as appropriate. Each drawing is only a schematic representation to the extent that the technology of this disclosure can be fully understood. Therefore, the technology of this disclosure is not limited to the illustrated examples. Furthermore, in this embodiment, explanations of configurations not directly related to this disclosure or well-known configurations may be omitted.

[0011] First, with reference to Figures 1 and 2, a specific example of the configuration of the testing system according to this embodiment will be described. In the following description, a testing system for examining the color development of a test strip, which is an example of a test specimen, will be used as an example. However, a testing system utilizing liquid chromatography or a testing system that photographs the target component and performs image analysis may also be used. The sample to be tested includes, for example, water and biological samples (urine, blood, body fluids, etc.). The target components in the sample include, for example, glycated hemoglobin in the blood and white blood cells, red blood cells, epithelial cells, etc., in the urine.

[0012] [First Embodiment] Figure 1 is a schematic perspective view showing an example of an inspection system 100 according to the first embodiment. The inspection system 100 according to this embodiment comprises an inspection device 10 and an information processing device 40. The inspection system 100 is installed, for example, in a medical facility such as a hospital, and the inspection device 10 and the information processing device 40 are connected via a communication line L. The inspection device 10 and the information processing device 40 may be connected in a way that allows communication using a LAN (Local Area Network), WAN (Wide Area Network), or the Internet.

[0013] As shown in Figure 1, the inspection device 10 in this embodiment integrally comprises a main body 1, a transport device 2, and an operating unit 20. The operating unit 20 may be separate from the main body 1, or it may be separated from the main body 1 and placed around the main body 1. The inspection device 10 is for performing qualitative testing of urine U contained in a container 30, and the transport device 2 is assembled to the front of the main body 1.

[0014] When urine U is used as the sample, the test strip used should be a urine test strip that includes reaction areas for multiple test items, such as urine protein, urine ketones, and urine glucose. The sample is not limited to urine U, but may also be a biological sample other than urine U (e.g., blood, plasma, and saliva).

[0015] The conveying device 2 is a device for conveying a rack 3, which holds a container 30 upright, along a fixed path. The conveying device 2 can have the same configuration as a conventionally known conveying device (for example, the conveying device described in Japanese Patent Application Publication No. 2009-229233), and the specific structural details are omitted. In the conveying device 2, once the rack 3 is placed in a predetermined starting area Sa, the rack 3 is then sequentially conveyed in the directions indicated by arrows N1 to N3, and finally reaches a predetermined ending area Ea. During the process of conveying the rack 3 in the direction of arrow N2, the suction nozzle 50 is used to collect urine U from the container 30.

[0016] The container 30 is provided with a label (not shown) printed with a barcode, for example. This label has subject identification information printed as a barcode to identify the subject who provided the urine U. The reading unit 16 is, for example, a barcode reader, and when the container 30 is transported in front of it, it reads the subject identification information from the label on the container 30. The suction nozzle 50 is for collecting a predetermined amount of urine U from the container 30 that has passed in front of the reading unit 16. The urine U collected by the suction nozzle 50 is supplied to a test strip for testing.

[0017] The operation unit 20 includes a display unit 21. The display unit 21 has a display screen such as a liquid crystal display panel and, for example, displays information to guide the operation of the operation unit 20. The urine U test results may be displayed on this display unit 21.

[0018] Figure 2 is a block diagram showing an example of the configuration of the inspection system 100 according to the first embodiment.

[0019] As shown in Figure 2, the main body 1 of the inspection apparatus 10 according to this embodiment includes a test piece supply device 4, a dispensing device 5, a control unit 6, a first optical measuring unit 7A, a second optical measuring unit 7B, a printer 11, a communication unit 12, a power supply unit 13, a storage unit 15, a reading unit 16, an operation unit 20, and an imaging unit 22.

[0020] The test piece supply device 4 is a device for supplying test strips (not shown) for urine testing to a predetermined location on the first optical measuring unit 7A. The dispensing device 5 is capable of collecting urine U from the container 30 using a suction nozzle 50 and dispensing (dotting) the collected urine U onto the test strip. The suction nozzle 50 is movable vertically and horizontally by a drive mechanism (not shown). The dispensing device 5 has a function for cleaning the suction nozzle 50. This configuration is similar to, for example, the dispensing device described in Japanese Patent Application Publication No. 2000-321270, and its details are omitted. In this embodiment, a second optical measuring unit 7B for urine color testing is provided at an intermediate point in the flow path (not shown) of the dispensing device 5.

[0021] The first optical measuring unit 7A is a measuring unit for detecting color reaction, which measures the color development state of the test paper under certain conditions. These certain conditions include, for example, that the amount of light irradiated onto the test paper is constant, that uniform light is irradiated onto the test paper, that the distance between the test paper and the light source is constant, and, in the case of a configuration that reads light reflection, that light of a wavelength suitable for measurement is used. Note that the inspection of the color development state is not limited to optical methods using the first optical measuring unit 7A; the color development state of the test paper may also be inspected from image data obtained by color imaging of the test paper using an imaging unit 22 such as a camera. The second optical measuring unit 7B for urine color testing is located in the middle of the flow path, and allows urine U aspirated by the suction nozzle 50 to flow into the cell (not shown) of the second optical measuring unit 7B.

[0022] The printer 11 prints the urine U test results and other specified data onto a designated sheet of paper 9. Note that the printer 11 is not a required component, and the system may be configured without it.

[0023] The control unit 6 includes a processor such as a CPU (Central Processing Unit), and performs operation control of each part of the inspection device 10 and various data processing according to a control program stored in the storage unit 15. The control unit 6 determines whether or not there is abnormal color development from spectral data obtained by optically measuring the color development state of the test paper with the first optical measurement unit 7A. Alternatively, the control unit 6 determines whether or not there is abnormal color development from image data obtained by photographing the color development state of the test paper with the imaging unit 22. Specifically, the control unit 6 may determine whether or not there is abnormal color development by, for example, whether or not the index value obtained from the spectral data or image data falls within a predetermined range of normal color development. In the case of image data, the determination may be made based on color space coordinates such as RGB, L*a*b, etc.

[0024] The storage unit 15 is accessible by the control unit 6 and stores control programs for controlling the operation of each part of the inspection device 10, various data processing, and various other data. The storage unit 15 may also be integrally provided within the control unit 6.

[0025] The communication unit 12 is a communication interface that connects to the information processing device 40 via a communication line L and connects to the server device described later in a communication manner. The power supply unit 13 is a power supply for supplying power to the inspection device 10, and is, for example, an AC power supply, a battery, etc.

[0026] On the other hand, the information processing device 40 is configured using, for example, a personal computer (PC). The information processing device 40 stores a subject information database (subject information DB) 41 that can be accessed from the testing device 10. The subject information DB 41 is used to manage or confirm various information about many subjects (including patients) who visit the medical facility where this testing system 100 is installed, such as subject identification information, medical visit history, prescription history, health checkup result history, and other information. The subject information DB 41 stores drug administration information administered to subjects. The drug administration information corresponds to the prescription history and includes information such as the name of the drug prescribed to the subject, the amount, the date of prescription, and the medical department that prescribed the drug.

[0027] The data registered in the subject information DB41 includes drug data showing the relationship between components in urine and drugs that affect the test results (i.e., color development) of those components. For example, the test result for glucose (GLU) in urine is likely to be false positive (i.e., abnormal color development) if the subject is taking thymiperone, and false negative if the subject is taking ascorbic acid or ambicillin. Reflecting these circumstances, the drug data lists drugs that affect the test result for "glucose" in urine, such as thymiperone, ascorbic acid, and ambicillin. Similarly, the drug data shows the correspondence between components in urine such as protein (PRO), urobilinogen (URO), bilirubin (BIL), creatinine (CRE), pH, occult blood (BLD), ketone bodies (KET), nitrite (NIT), and white blood cells (LEU), and drugs that are likely to adversely affect the test results of each component. This drug data is referenced after the urine urine test is completed and used to determine whether the urine urine test results were affected by the subject's drug administration.

[0028] However, since the patient information DB41 only registers drugs whose correlation with abnormal coloration is known, in medical facilities where the knowledge and expertise of the testing staff have not been sufficiently accumulated, or in the case of a new drug, the drug data in the patient information DB41 may not be updated, making it difficult to identify the drug corresponding to the abnormal coloration.

[0029] In response to this, if the spectral data or image data of the test strip contains abnormal coloration and the drug corresponding to the abnormal coloration cannot be identified from the subject information DB 41, the control unit 6 displays the image data or spectral data of the test strip on the display unit 21 and accepts comments from the test staff regarding the displayed image data or spectral data. Here, "comments" include drug information about new drugs. Comments may be entered directly from the testing device 10 or from the information processing device 40. In certain medical facilities where there are test staff with extensive knowledge and expertise about drugs, it is possible to enter comments that include drug information about new drugs.

[0030] Figure 3 shows an example of image data and comments for a test strip according to this embodiment. In the example shown in Figure 3, image data including abnormal coloration is displayed, and comments corresponding to the abnormal coloration are shown. The control unit 6 stores the image data including the abnormal coloration and the comments including drug information in the storage unit 15 in association with each other. If a similar abnormal coloration is detected in subsequent image data, a flag indicating the abnormal coloration may be automatically output.

[0031] Figure 4 shows an example of printing that includes a flag indicating abnormal color development. In the example printing shown in Figure 4, information A1 to A10 is printed, and flag A11, which indicates abnormal color development, is printed. Information A1 shows the abnormality mark, measurement type, and measurement number, and information A2 shows the subject identification information, which is the ID. Information A3 shows the measurement date, measurement time, and ambient temperature, and information A4 shows the port number (rack number - port number), test strip type, and feeder number. Information A5 shows the measurement result of the test strip (item abnormality mark, measurement item name, qualitative value, semi-qualitative value, or reflectance), and information A6 shows turbidity (turbidity abnormality mark, qualitative value, turbidity measurement value, or error). Note that reflectance and turbidity measurement values ​​are printed when "reflectance" is specified in the display format. Information A7 shows specific gravity (specific gravity abnormality mark, specific gravity measurement value, or error), and information A8 shows the color tone. Information A9 shows an error, and information A10 shows drug information.

[0032] Next, with reference to Figures 5 and 6, a drug information provision system according to the first embodiment will be described.

[0033] Figure 5 shows an example of the configuration of a drug information provision system 200 according to the first embodiment. The drug information provision system 200 according to this embodiment comprises a testing system 100 and a server device 60. The testing system 100 comprises a testing device 10 and an information processing device 40, and the testing device 10 (or information processing device 40) and the server device 60 are connected to communicate via a network N. The network N is, for example, a network such as the Internet, LAN, or WAN. The server device 60 according to this embodiment is configured, for example, as a server computer on the cloud.

[0034] As shown in Figure 5, the server device 60 includes a CPU 61, a ROM (Read Only Memory) 62, a RAM (Random Access Memory) 63, an input / output interface (I / O) 64, a storage unit 65, a display unit 66, an operation unit 67, and a communication unit 68. Note that the CPU 61 is an example of a processor and may be a GPU (Graphics Processing Unit), or a combination of a CPU and a GPU.

[0035] The CPU 61, ROM 62, RAM 63, and I / O 64 are connected to each other via a bus. The I / O 64 is connected to various functional units, including a storage unit 65, a display unit 66, an operation unit 67, and a communication unit 68. These functional units are capable of communicating with the CPU 61 via the I / O 64.

[0036] The control unit is comprised of a CPU 61, ROM 62, RAM 63, and I / O 64. The control unit may be configured as a sub-control unit that controls the operation of a part of the server device 60, or as part of a main control unit that controls the operation of the entire server device 60. Some or all of the blocks of the control unit may use integrated circuits such as LSIs (Large Scale Integration) or IC (Integrated Circuit) chipsets. Individual circuits may be used for each of the above blocks, or some or all of them may be integrated into a single circuit. The above blocks may be provided as a single unit, or some of the blocks may be provided separately. Furthermore, parts of each of the above blocks may be provided separately. For the integration of the control unit, dedicated circuits or general-purpose processors may be used, not just LSIs.

[0037] For example, an HDD, SSD, or flash memory can be used as the storage unit 65. The drug information provision program 65A according to this embodiment is stored in the storage unit 65. This drug information provision program 65A may also be stored in ROM 62.

[0038] The drug information provision program 65A may be pre-installed on the server device 60, for example. The drug information provision program 65A may also be implemented by storing it on a non-volatile storage medium or distributing it via the network N and installing it on the server device 60 as appropriate. Examples of non-volatile storage mediums include CD-ROM (Compact Disc Read Only Memory), magneto-optical disk, HDD, DVD-ROM (Digital Versatile Disc Read Only Memory), flash memory, memory card, etc.

[0039] The display unit 66 may use, for example, a liquid crystal display (LCD), an organic EL display, or the like. The display unit 66 may also have an integrated touch panel. The operation unit 67 is equipped with, for example, a keyboard or mouse for inputting operations. The display unit 66 and the operation unit 67 receive various instructions from the user of the server device 60. The display unit 66 displays various information such as the results of processing performed in response to the instructions received from the user, and notifications regarding the processing.

[0040] The communication unit 68 is connected to a network N such as the Internet, LAN, or WAN, and is capable of communicating with the inspection device 10 of the inspection system 100 via the network N.

[0041] Here, we assume a case where the testing system 100 cannot identify the drug that is causing the abnormal coloration of the test strip. In this case, the testing device 10 transmits image data or spectral data indicating that the coloration of the test strip is abnormal to the server device 60. The server device 60 according to this embodiment receives the image data or spectral data from the testing device 10 of the testing system 100, creates drug information regarding the drug that is causing the abnormal coloration of the test strip based on the received image data or spectral data, and transmits the created drug information to the testing device 10.

[0042] Specifically, the CPU 61 of the server device 60 according to this embodiment functions as the various parts shown in Figure 6 by writing the drug information provision program 65A stored in the storage unit 65 to the RAM 63 and executing it.

[0043] FIG. 6 is a block diagram showing an example of the functional configuration of the server device 60 according to the first embodiment. In the present embodiment, a form of providing drug information corresponding to image data or spectral data using machine learning will be described. The server device 60 is connected to each of a plurality of inspection systems 100.

[0044] As shown in FIG. 6, the CPU 61 of the server device 60 according to the present embodiment functions as a collection unit 61A, a learning unit 61B, a reception unit 61C, a creation unit 61D, and a transmission unit 61E.

[0045] First, the learning process of drug information will be described. The collection unit 61A collects image data or spectral data indicating that the color development state of the test paper is abnormally developed, and a comment including drug information, from each of the plurality of inspection systems 100. The comment may include subject information acquired from the subject information DB 41. The comment is input from the user by the inspection device 10 or the information processing device 40. Specifically, the collection unit 61A may collect image data or spectral data, and a comment, from each of the plurality of inspection systems 100 at a predetermined timing. The "predetermined timing" here may be, for example, a regular timing such as every week or every month, or may be the timing when a new comment is input.

[0046] The learning unit 61B generates a learned model 65B by performing machine learning on learning data in which the image data or spectral data collected by the collection unit 61A is associated with a comment including drug information. The learned model 65B is a model that takes image data or spectral data as an input and outputs drug information corresponding to the image data or spectral data. The learned model 65B is not particularly limited, but for example, a neural network or the like is used. The learning unit 61B stores the generated learned model 65B in the storage unit 65, for example.

[0047] Next, the process of providing drug information will be described. The receiving unit 61C receives image data or spectral data indicating that the color development state of the test strip is abnormal from a certain inspection system 100.

[0048] The creating unit 61D creates drug information regarding drugs that affect the abnormal color development of the test strip from the image data or spectral data received by the receiving unit 61C. In the present embodiment, the learned model 65B is used to create the drug information.

[0049] The transmitting unit 61E transmits the drug information created by the creating unit 61D to the inspection system 100. Note that the transmitting unit 61E may transmit a flag indicating that the test strip is abnormally colored, as shown in FIG. 4 above, together with the drug information created by the creating unit 61D.

[0050] The inspection device 10 (or the information processing device 40) of the inspection system 100 displays the drug information received from the server device 60 together with the corresponding image data or spectral data.

[0051] FIG. 7 is a diagram showing an example of the image data and drug information displayed on the inspection device 10. In the example of FIG. 7, drug information regarding drugs that affect abnormal color development is displayed together with image data, which is an example of color development data.

[0052] [[ID=]]Next, the operation of the drug information providing system 200 according to the first embodiment will be described with reference to FIGS. 8 and 9.

[0053] FIG. 8 is a flowchart showing an example of the flow of drug information learning processing by the drug information providing program 65A according to the first embodiment.

[0054] When the execution of the drug information learning processing by the drug information providing program 65A of the server device 60 is instructed, the CPU 61 reads out and executes the drug information providing program 65A stored in the storage unit 65.

[0055] In step S101 of Figure 8, the CPU 61 collects, as an example, image data, which is an example of color development data, and comments, which include drug information, from each of the multiple inspection systems 100, as shown in Figure 3 above. The image data is data indicating that the color development state of the test strip is abnormal, and the drug information is information about drugs that affect the abnormal color development. However, spectral data may be used instead of image data for the color development data.

[0056] In step S102, the CPU 61 generates a trained model 65B by machine learning training data that associates the image data collected in step S101 with comments containing drug information. The trained model 65B is a model that takes image data as input and outputs drug information corresponding to the image data.

[0057] In step S103, the CPU 61 stores the trained model 65B created in step S102 in the storage unit 65 and terminates the drug information learning process by the drug information provision program 65A.

[0058] Figure 9 is a flowchart showing an example of the drug information provision process by the drug information provision program 65A according to the first embodiment.

[0059] When the server device 60 is instructed to execute the drug information provision process using the drug information provision program 65A, the CPU 61 reads the drug information provision program 65A stored in the storage unit 65 and executes it.

[0060] In step S111 of Figure 9, the CPU 61 receives image data from a certain inspection system 100 indicating that the color development of the test paper is abnormal. However, spectral data may be used instead of image data.

[0061] In step S112, the CPU 61 uses the trained model 65B to create drug information regarding drugs that affect abnormal coloration based on the image data received in step S111.

[0062] In step S113, the CPU 61 transmits the drug information created in step S112 to the inspection system 100, and the drug information provision process by the drug information provision program 65A ends. The inspection device 10 (or information processing device 40) of the inspection system 100 displays the drug information received from the server device 60 together with the corresponding image data, as shown in Figure 7 above, for example.

[0063] Thus, according to this embodiment, even in medical facilities where the knowledge and expertise of the inspectors are not sufficiently accumulated, or in the case of new drugs, the drug causing the abnormal coloration can be easily identified using a trained model.

[0064] The server device 60, the inspection device 10, or the information processing device 40 may register a group of images as sample images (so-called atlas images) that associate image data indicating that the color development of the test strip is abnormal with comments containing drug information. The inspector may refer to the sample images as needed and identify the drug that is affecting the abnormal color development from the sample images.

[0065] [Second Embodiment] In the first embodiment described above, a method for identifying drugs using a trained model was explained, but in the second embodiment, a method for identifying drugs using a rule-based approach will be explained.

[0066] Figure 10 is a block diagram showing an example of the functional configuration of the server device 60A according to the second embodiment. In this embodiment, a configuration in which drug information corresponding to image data or spectral data is provided using a data table will be described. The server device 60A is connected to each of the multiple inspection systems 100.

[0067] As shown in Figure 10, the CPU 61 of the server device 60A according to this embodiment functions as a collection unit 61A, a generation unit 61F, a receiving unit 61C, a creation unit 61D, and a transmission unit 61E.

[0068] First, let's explain the drug information learning process. As described above, the collection unit 61A collects image data or spectral data indicating that the color development state of the test strip is abnormal, as well as comments containing drug information, from each of the multiple testing systems 100.

[0069] The generation unit 61F generates a data table 65C that associates image data or spectral data collected by the collection unit 61A with comments containing drug information, and stores the generated data table 65C in, for example, the storage unit 65. By referring to the data table 65C, it is possible to identify drug information corresponding to image data with similar color development states.

[0070] Next, the process for providing drug information will be explained. The receiving unit 61C receives image data or spectral data from a certain testing system 100 that indicates that the color development state of the test strip is abnormal.

[0071] The creation unit 61D creates drug information regarding drugs that affect the abnormal color development of the test strips based on the image data or spectral data received by the receiving unit 61C. In this embodiment, drug information is created using a data table 65C.

[0072] The transmission unit 61E transmits the drug information created by the creation unit 61D to the inspection system 100.

[0073] The inspection device 10 (or information processing device 40) of the inspection system 100 displays the drug information received from the server device 60 together with the corresponding image data or spectral data.

[0074] Thus, according to this embodiment, even in medical facilities where the knowledge and expertise of the inspectors are not sufficiently accumulated, or in the case of new drugs, the drug causing the abnormal coloration can be easily identified using the data table.

[0075] The drug information provision system and server device according to the embodiment have been described with illustrative examples. The embodiment may be in the form of a program that causes a computer to execute the functions of each part of the server device, or in the form of a program product containing said program. The embodiment may be in the form of a computer-readable non-temporary storage medium that stores these programs.

[0076] Furthermore, the server device configuration described in the above embodiment is merely an example and may be modified as needed without departing from the main purpose.

[0077] Furthermore, the program processing flow described in the above embodiment is just one example, and unnecessary steps may be deleted, new steps added, or the processing order rearranged, as long as it does not deviate from the main purpose.

[0078] Furthermore, although the above embodiment describes a case in which the process according to the embodiment is realized by a software configuration using a computer by executing a program, the embodiment is not limited to this. The embodiment may also be realized by a hardware configuration or a combination of a hardware configuration and a software configuration.

[0079] The following additional information is disclosed regarding the embodiments described above.

[0080] (Note 1) A drug information provision system comprising an inspection system for inspecting a sample and a server device communicated with the inspection system, wherein the server device includes: a receiving unit that receives color data from the inspection system indicating that the color development state of a test piece to which the sample has been applied is abnormal; a creation unit that creates drug information relating to a drug that affects the abnormal color development of the test piece based on the color data received by the receiving unit; and a transmission unit that transmits the drug information created by the creation unit to the inspection system. (Note 2) The drug information provision system according to Note 1, wherein the inspection system displays the drug information received from the server device together with the corresponding color data. (Note 3) The server device is connected to each of the multiple inspection systems, and the server device further comprises: a collection unit that collects color data acquired by each of the multiple inspection systems and comments including drug information that each of the multiple inspection systems accepts as input; and a learning unit that generates a trained model that takes color data as input and outputs drug information corresponding to the color data by machine learning training data that associates the color data with the comments, and the creation unit uses the trained model to create drug information corresponding to the color data received from the inspection systems, the drug information provision system according to Note 1 or Note 2. (Note 4) The server device is connected to each of the multiple inspection systems, and the server device further comprises: a collection unit that collects color development data acquired by each of the multiple inspection systems and comments including drug information that each of the multiple inspection systems accepts as input; and a storage unit that stores a data table associating the color development data and the comments, and the creation unit uses the data table to create drug information corresponding to the color development data received from the inspection systems, the drug information provision system according to Note 1 or Note 2. (Note 5) The collection unit collects the color development data and the comments from each of the multiple inspection systems at predetermined timings, the drug information provision system according to Note 3 or Note 4.(Note 6) The drug information provision system according to any one of Notes 1 to 5, wherein the transmitting unit transmits a flag indicating that the test piece is abnormally colored, along with the drug information created by the creation unit. (Note 7) The drug information provision system according to any one of Notes 1 to 6, wherein the color data is image data obtained by photographing the color state of the test piece, or spectral data obtained by optically measuring the color state of the test piece. (Note 8) A drug information creation method by a drug information provision system including an inspection system for inspecting a sample and a server device communicated with the inspection system, wherein the server device receives color data from the inspection system indicating that the color state of the test piece to which the sample has been applied is abnormally colored, creates drug information relating to a drug that affects the abnormal coloration of the test piece based on the received color data, and transmits the created drug information to the inspection system. (Note 9) A drug information provision program for a drug information provision system including an inspection system for inspecting samples and a server device that is communicatively connected to the inspection system, the drug information provision program causing the server device to perform the following processes: receive color data from the inspection system indicating that the color development state of a test piece to which the sample has been applied is abnormal; create drug information relating to a drug that affects the abnormal color development of the test piece based on the received color data; and transmit the created drug information to the inspection system.

[0081] The disclosure of Japanese Patent Application No. 2024-167692, filed on 26 September 2024, is incorporated herein by reference in its entirety. All documents, patent applications, and technical standards described herein are incorporated herein by reference to the same extent as if each individual document, patent application, and technical standard were specifically and individually noted to be incorporated by reference.

Claims

1. A drug information provision system comprising an inspection system for inspecting samples and a server device communicated with the inspection system, wherein the server device includes: a receiving unit that receives color data from the inspection system indicating that the color development state of a test piece to which the sample has been applied is abnormal; a creation unit that creates drug information relating to drugs that affect the abnormal color development of the test piece based on the color data received by the receiving unit; and a transmission unit that transmits the drug information created by the creation unit to the inspection system.

2. The drug information provision system according to claim 1, wherein the inspection system displays drug information received from the server device together with corresponding color development data.

3. The server device is connected to each of a plurality of inspection systems, and the server device further comprises: a collection unit that collects color data acquired by each of the plurality of inspection systems and comments including drug information that each of the plurality of inspection systems accepts as input; and a learning unit that generates a trained model that takes color data as input and outputs drug information corresponding to the color data by machine learning training data that associates the color data with the comments, and the creation unit uses the trained model to create drug information corresponding to the color data received from the inspection systems, the drug information provision system according to claim 1.

4. The server device is connected to each of a plurality of inspection systems, and the server device further comprises: a collection unit that collects color development data acquired by each of the plurality of inspection systems and comments including drug information that each of the plurality of inspection systems accepts as input; and a storage unit that stores a data table associating the color development data with the comments, and the creation unit uses the data table to create drug information corresponding to the color development data received from the inspection systems, the drug information provision system according to claim 1.

5. The drug information provision system according to claim 3 or 4, wherein the collection unit collects the color development data and the comments from each of the plurality of inspection systems at predetermined timings.

6. The drug information provision system according to claim 1, wherein the transmitting unit transmits a flag indicating that the test piece is abnormally colored, along with the drug information created by the creation unit.

7. The drug information provision system according to claim 1, wherein the color development data is image data obtained by photographing the color development state of the test piece, or spectral data obtained by optically measuring the color development state of the test piece.

8. A method for creating drug information using a drug information provision system that includes an inspection system for inspecting a sample and a server device that is communicatively connected to the inspection system, wherein the server device receives color data from the inspection system indicating that the color development state of a test piece to which the sample has been applied is abnormal, creates drug information relating to a drug that affects the abnormal color development of the test piece based on the received color data, and transmits the created drug information to the inspection system.

9. A drug information provision program for a drug information provision system including an inspection system for inspecting samples and a server device that is communicatively connected to the inspection system, the drug information provision program causing the server device to perform the following processes: receive color data from the inspection system indicating that the color development state of a test piece to which the sample has been applied is abnormal; create drug information relating to a drug that affects the abnormal color development of the test piece based on the received color data; and transmit the created drug information to the inspection system.

Images